Latest Breaking News On - Uot there isa huge unmet clinical need for the first line treatment of advanced or metastatic escc results orient 15 demonstrated that sintilimab can bring significant benefit to today - Page 1 : comparemela.com
SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY) today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for TYVYT (sintilimab injection) in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is the fifth NMPA-approved indication of TYVYT. In China, TYVYT was approved for: the treatment of relapsed or refractory classical Hodgkin's lymphoma in Dece